BidaskClub cut shares of MediciNova (NASDAQ:MNOV) from a strong-buy rating to a buy rating in a research report report published on Wednesday.
Separately, ValuEngine upgraded MediciNova from a sell rating to a hold rating in a report on Wednesday, February 7th.
Shares of MNOV stock opened at $11.69 on Wednesday. MediciNova has a fifty-two week low of $4.40 and a fifty-two week high of $14.50.
WARNING: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3296775/medicinova-mnov-cut-to-buy-at-bidaskclub.html.
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.